MDMA for PTSD Showing Promising Outcomes for Patients in MAPS Phase 3 Trials
“In the pharmaceutical drug development community, this is what you dream about.”
Mental Health - Page 11
Noribogaine is More Effective Than Fluoxetine in Reducing Depressive Symptoms in Rat Model
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
Antidepressant-Like Effect with A Single Dose of Ibogaine and Noribogaine in Rats
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
The Structure and Function of the Serotonin 5-HT2C Receptor
5-HT2C has a role in the psychedelic effect. Understanding it is essential for harnessing the full benefits of nature’s chemical cocktails.
Psilocybin Superior to Ketamine for Prolonged Antidepressant-Like Effects (Rodent Model)
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Psilocybin Mindfulness Negatively Correlated with 5-HT2A Binding, Study Finds
Results hint at a possible mechanism for the persistent effect that psilocybin has on mindfulness.
Psychedelics May Aid in Deprogramming Addiction
Recent evidence suggests psychedelics may significantly improve addiction treatment outcomes.
Emotional Adjustment: The Modulatory Influence of Psilocybin on the Amygdala
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
Positive Effects of Single-Dose Psilocybin Last Nearly 5 Years
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
The Medical University of South Carolina is Launching a Psychedelic Research Center
Scheduled to open in 2021, the new center will study the therapeutic potential of MDMA, psilocybin, DMT, and mescaline.